|
|
Article: Avigen and Johns Hopkins Scientists Report Gene Therapy Progress in Treating Heart Disease at American Heart Association Meeting
- Article from:
- PR Newswire
- Article date:
- November 11, 1996
CopyrightCOPYRIGHT 1996 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ALAMEDA, Calif., Nov. 11 /PRNewswire/ -- Avigen, Inc. (Nasdaq: AVGN) scientists in conjunction with researchers at John Hopkins School of Medicine today announced the successful application of their gene therapy technology in the treatment of heart disease. In a paper presented at today's session of the American Heart Association's 69th Annual Meeting in New Orleans, Johns Hopkins and Avigen scientists reported on the successful delivery and sustained expression of a gene associated with an inherited fatal heart disease in children known as Pompe's disease in experimental models. Characterized by an enlargement and weakening of the heart muscle in infants, Pompe's ...
Related newspaper, magazine, and journal articles:
|
|
Article: Avigen Reports Financial Results for the Three and Nine ...
PR Newswire;
October 30, 2002 ;
700+ words
...Cash and Securities of $126 Million Avigen, Inc. , the leader in AAV gene delivery ... September 30, 2002. At September 30, 2002, Avigen had $126 million in cash, cash equivalents ... the end of the previous quarter. "Avigen continues to make progress on a number ...
|
|